RecruitingPhase 1NCT07441694

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Sponsor

Incyte Corporation

Enrollment

218 participants

Start Date

May 11, 2026

Study Type

INTERVENTIONAL

Conditions

Myeloproliferative Neoplasms

Summary

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCA036978 and a drug called Standard disease-directed therapy for people with myeloproliferative neoplasms. The study is currently recruiting participants at 49 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA036978

INCA036978 will be administered at protocol defined dose.

DRUGStandard disease-directed therapy

A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Locations(54)

University of Alabama At Birmingham

Birmingham, Alabama, United States

City of Hope-Lennar Foundation Cancer Center

Irvine, California, United States

Usc Norris Comprehensive Cancer Center

Los Angeles, California, United States

UCLA Medical Hematology & Oncology

Los Angeles, California, United States

Yale Cancer Center

New Haven, Connecticut, United States

University of Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

John Hopkins Hospital

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Mount Sinai School of Medicine

New York, New York, United States

Weill Cornell Medicine

New York, New York, United States

University of North Carolina At Chapel Hill

Chapel Hill, North Carolina, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy

Durham, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Tristar Bmt/Tcto

Nashville, Tennessee, United States

University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Concord General Repatriation Hospital

Concord, New South Wales, Australia

Royal North Shore Hospital

St Leonards, New South Wales, Australia

Icon Cancer Centre

Auchenflower, Queensland, Australia

Epworth Health Care

East Melbourne, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

Centre Hospitalier Universitaire (Chu) de Liege

Liège, Belgium

AZ DELTA

Roeselare, Belgium

Princess Margaret Cancer Center

Toronto, Ontario, Canada

McGill University Jewish General Hospital

Montreal, Quebec, Canada

Institut Bergonie

Bordeaux, France

Hospital Saint Louis

Paris, France

Institut Gustave Roussy

Villejuif, France

University Medical Center Rwth Aachen

Aachen, Germany

Charite Universitaetsmedizin Berlin - Campus Charite Mitte

Berlin, Germany

Universitatklinikum Freiburg

Freiburg im Breisgau, Germany

Universitatsklinikum Halle (Saale)

Halle, Germany

Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

Mainz, Germany

Aou Policlinico S. Orsola-Malpighi

Bologna, Italy

Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico

Milan, Italy

A. Gemelli University Hospital, Catholic University of the Sacred Heart

Roma, Italy

Azienda Sanitaria Universitaria Friuli Centrale Asu Fc

Udine, Italy

National Cancer Center Hospital East

Kashiwa Chiba, Japan

Ehime University Hospital

Toon, Ehime, Japan

Seoul National University Hospital

Jongno-gu, Seoul, South Korea

The Catholic University of Korea Seoul St. Mary'S Hospital

Seocho-gu, Seoul, South Korea

Hospital Universitari Germans Trias I Pujol

Badalona, Spain

Hospital Universitario de Gran Canaria Dr. Negrin

Las Palmas de Gran Canaria, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust

London, United Kingdom

Nottingham University Hospitals

Nottingham, United Kingdom

University of Oxford

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07441694

Related Trials

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT0700811826 locations

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT033149741 location

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT0631359330 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0603400213 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0593635929 locations